"Carcinosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
| Descriptor ID |
D002296
|
| MeSH Number(s) |
C04.557.435.290 C04.557.450.795.290
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carcinosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Carcinosarcoma".
This graph shows the total number of publications written about "Carcinosarcoma" by people in this website by year, and whether "Carcinosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinosarcoma" by people in Profiles.
-
Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous Component. Am J Surg Pathol. 2025 May 01; 49(5):439-447.
-
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma. Int J Gynecol Cancer. 2025 Mar; 35(3):101672.
-
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecol Oncol. 2023 03; 170:38-45.
-
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecol Oncol. 2023 02; 169:98-105.
-
Comprehensive Molecular Profiling of Sinonasal Teratocarcinosarcoma Highlights Recurrent SMARCA4 Inactivation and CTNNB1 Mutations. Am J Surg Pathol. 2023 02 01; 47(2):224-233.
-
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecol Oncol. 2022 07; 166(1):117-125.
-
SALL-4 and Beta-Catenin Expression in Sinonasal Teratocarcinosarcoma. Head Neck Pathol. 2022 Mar; 16(1):229-235.
-
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486.
-
Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37.
-
Novel targeted therapies in ovarian and uterine carcinosarcomas. Discov Med. 2018 Jun; 25(140):309-319.